NOV 08, 2019 8:00 AM PST

Polygenic Risk Score analysis for Alzheimer's disease risk

Speaker
  • CEO, Cytox Ltd
    Biography
      Richard Pither has been involved in the development of diagnostic and therapeutic pharmaceutical products for more than 25 years. He has been CEO at Cytox for the past 7 years, a precision medicine working on developing and commercialising a new diagnostic technology for assessing Alzheimer's Disease risk. Prior to Cytox, Richard has held senior R&D and leadership positions in global pharmaceutical companies including GE Healthcare/Amersham plc, Lorantis and UCB-Celltech. During this time, he was involved in the development of a novel 18F-PET radiopharmaceutical for imaging amyloid deposition in the brains of Alzheimer's disease patients.

    Abstract
    DATE:  November 8, 2019
    TIME:  8:00am PT, 11:00am ET
     
    The utility of Polygenic Risk Scores (PRS) is gaining researchers' attention for identifying individual genetic risk and disease risk prediction in Alzheimer's Disease (AD) at both the early and pre-symptomatic stages of the disease. genoSCORE™ combines Cytox's proprietary technologies variaTECT™, a proprietary single nucleotide polymorphism (SNP) profiling array built on the Axiom platform from Thermo Fisher Scientific, with the SNPfitR™ analytical and interpretive software incorporating algorithms developed in partnership with Cardiff University, to give a PRS that identifies any individual's genetic risk of developing AD from blood or saliva-extracted DNA. This can help in patient stratification for clinical trial research to develop targeted treatments for AD.
     
    Learning Objectives:
    • Select the highest risk APOE3/E4 subjects mostly likely to develop AD
    • Identify highest/low risk APOE3/E3 subjects for inclusion/exclusion in clinical studies
     
     
    Webinars will be available for unlimited on-demand viewing after live event.
     
    LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

    Show Resources
    You May Also Like
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    JUN 23, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 23, 2020 10:00 AM PDT
    DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
    JUN 09, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 09, 2020 10:00 AM PDT
    DATE: June 9, 2020 TIME: 10:00am PT, 1:00pm ET The presentation will first discuss sepsis as a disease and then explain the importance of performing diagnostic tests in the clinical labora...
    JUN 09, 2020 3:00 PM CEST
    C.E. CREDITS
    JUN 09, 2020 3:00 PM CEST
    DATE: June 9, 2020 TIME: 6am PT, 9am ET, 3pm CEST The importance of disposable plastic consumables and their overall impact on the experimental workflow of qPCR has been taken into considera...
    MAY 13, 2020 4:00 PM CEST
    C.E. CREDITS
    MAY 13, 2020 4:00 PM CEST
    DATE: May 13, 2020 TIME: 7am PT, 10am ET, 4pm CEST Stem cells represent an important tool in a wide range of applications, including basic research, disease modeling, drug discovery, and reg...
    Loading Comments...
    Show Resources
    Attendees
    • See more